SULFADOXINE, 500mg / PYRIMETHAMINE, 25mg, tab.

STD DORASULP5T-

Valid Article

Former Code(s): -X

Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BD51
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://www.unicat.msf.org/web/image/product.template/572887/image_1920?unique=1b92d69

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

SULFADOXINE / PYRIMETHAMINE (SP) pregnancy

Therapeutic Action

Fixed-dose combination (FDC) of two antimalarials

Indications

Intermittent Preventive Treatment of malaria in Pregnant women (SP-IPTp), from the second trimester onwards in areas with moderate-to-high Plasmodium falciparum malaria transmission in countries in Sub-Saharan Africa.

Instructions for use

The 500mg dispersible tablet is preferred to the normal 500mg tablet.

Resistance to sulfadoxine/pyrimethamine is becoming more and more frequent.

Precautions for Use

Contraindicated during the first trimester of pregnancy due to the risk of neural tube defects.

Do not use in combination with co-trimoxazole.

The dosage Sulfadoxine 250mg / Pyrimethamine 12.5mg is reserved for the Perennial Malaria Chemoprevention - PMC (formerly called SP-IPTi) in children under 24 months of age.

Storage

Below 25°C ‐ Protect from sunlight